Hookipa Pharma Inc (HOOK) - Net Assets
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has net assets worth $28.68 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($52.71 Million) and total liabilities ($24.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Hookipa Pharma Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $28.68 Million |
| % of Total Assets | 54.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -63.7% |
| 10-Year Change | N/A |
| Growth Volatility | 68.61 |
Hookipa Pharma Inc - Net Assets Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore HOOK current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Hookipa Pharma Inc (2017–2025)
The table below shows the annual net assets of Hookipa Pharma Inc from 2017 to 2025. For live valuation and market cap data, see Hookipa Pharma Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $32.52 Million | -36.50% |
| 2024-12-31 | $51.21 Million | -43.00% |
| 2023-12-31 | $89.86 Million | -12.35% |
| 2022-12-31 | $102.52 Million | +14.43% |
| 2021-12-31 | $89.59 Million | -42.61% |
| 2020-12-31 | $156.12 Million | +32.42% |
| 2019-12-31 | $117.90 Million | +165.54% |
| 2018-12-31 | $44.40 Million | +204.09% |
| 2017-12-31 | $-42.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hookipa Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38285600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Comprehensive Income | $-9.70 Million | -29.83% |
| Other Components | $468.82 Million | 1441.59% |
| Total Equity | $32.52 Million | 100.00% |
Hookipa Pharma Inc Competitors by Market Cap
The table below lists competitors of Hookipa Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LX Hausys Ltd Preferred
KO:108675
|
$11.82 Million |
|
Amalgamated Industrial Steel Berhad
KLSE:2682
|
$11.83 Million |
|
Value8 N.V
AS:PREVA
|
$11.84 Million |
|
ABERA BIOSCIENCE AB
F:8WK
|
$11.85 Million |
|
Putra Rajawali Kencana PT
JK:PURA
|
$11.82 Million |
|
Mobio Technologies Inc
V:MBO
|
$11.81 Million |
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
$11.81 Million |
|
Riley Gold Corp
V:RLYG
|
$11.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hookipa Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 51,214,000 to 32,521,000, a change of -18,693,000 (-36.5%).
- Net loss of 13,837,000 reduced equity.
- Other comprehensive income decreased equity by 4,613,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.84 Million | -42.55% |
| Other Comprehensive Income | $-4.61 Million | -14.18% |
| Other Changes | $-243.00K | -0.75% |
| Total Change | $- | -36.50% |
Book Value vs Market Value Analysis
This analysis compares Hookipa Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-467.84 | $1.19 | x |
| 2018-12-31 | $485.56 | $1.19 | x |
| 2019-12-31 | $66.01 | $1.19 | x |
| 2020-12-31 | $59.96 | $1.19 | x |
| 2021-12-31 | $27.29 | $1.19 | x |
| 2022-12-31 | $15.65 | $1.19 | x |
| 2023-12-31 | $9.51 | $1.19 | x |
| 2024-12-31 | $4.08 | $1.19 | x |
| 2025-12-31 | $2.57 | $1.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hookipa Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -142.63%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.29x
- Recent ROE (-42.55%) is above the historical average (-50.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.46 Million |
| 2018 | -36.57% | -212.83% | 0.11x | 1.54x | $-20.68 Million |
| 2019 | -28.96% | -285.94% | 0.08x | 1.22x | $-45.94 Million |
| 2020 | -21.65% | -172.59% | 0.10x | 1.20x | $-49.41 Million |
| 2021 | -84.46% | -410.16% | 0.15x | 1.41x | $-84.63 Million |
| 2022 | -63.55% | -457.19% | 0.08x | 1.66x | $-75.40 Million |
| 2023 | -90.79% | -405.29% | 0.12x | 1.80x | $-90.57 Million |
| 2024 | -84.94% | -98.99% | 0.53x | 1.61x | $-48.62 Million |
| 2025 | -42.55% | -142.63% | 0.23x | 1.29x | $-17.09 Million |
Industry Comparison
This section compares Hookipa Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hookipa Pharma Inc (HOOK) | $28.68 Million | 0.00% | 0.84x | $11.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more